Pulmonary fibrosis patients rate support program in new study
NCT ID NCT06912659
First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This study follows 157 adults with pulmonary fibrosis who are taking nintedanib and enrolled in a patient support program in Spain. Researchers will measure how satisfied patients are with the program and monitor their quality of life, depression symptoms, and side effects over 12 months. The goal is to understand how helpful the program is, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Evidenze Health Espana S.L.
Barcelona, 08005, Spain
Conditions
Explore the condition pages connected to this study.